



OPEN

Author Correction: Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study

Published online: 05 May 2021

Andrew McGarry, John Gaughan, Cory Hackmyer, Jacqueline Lovett, Mohammed Khadeer, Hamza Shaikh, Basant Pradhan, Thomas N. Ferraro, Irving W. Wainer & Ruin Moadel

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-020-77526-9>, published online 24 November 2020

This Article contains errors in the last sentence from the Introduction section.

"This was carried out using several metabolomic platforms (Biocrates p180 kit, ABSciex Lipidlyzer platform, LC-MS/MS method for NAD⁺ and kynurenone) in both plasma and the corresponding CSF from participants with HD ranging from TFC Stage I (mild) to IV (severe)."

should read:

"This was carried out using several metabolomic platforms (Biocrates p180 kit, ABSciex Lipidlyzer platform, LC-MS/MS method for NAD⁺ and kynurenone) in both plasma and the corresponding CSF from participants with HD ranging from TFC Stage I (mild) to III (moderate-severe)."

Secondly, in the first paragraph of the Results section,

"Baseline TFC ranged from 3 to 13; three participants were HD Stage I (scores 12, 13, 13), four were Stage II (7, 8, 8, 9), four Stage III (4, 5, 6, 6), and one Stage IV (3)."

should read:

"Baseline TFC ranged from 3 to 13; three participants were HD Stage I (scores 12, 13, 13), four were Stage II (7, 8, 8, 9), and five Stage III (3, 4, 5, 6, 6)."

Furthermore, in the first sentence of the Discussion section,

"To our knowledge, this pilot study is the first report in HD correlating metabolomic changes in plasma and CSF with clinical progression across both early (HD1 and 2) and more advanced stages (HD3 and 4) of the disease."

should read:

"To our knowledge, this pilot study is the first report in HD correlating metabolomic changes in plasma and CSF with clinical progression across both early (HD1 and 2) and more advanced stages (HD3) of the disease."

Lastly, in the Methods section,

“Scores range from 13 (normal) to 0 (total incapacitation) and define stages of the disease: HD1 (TFC 11–13, early mild), HD2 (TFC 7–10, mild), HD3 (TFC 4–6, moderate, and HD4 (0–3, severe).”

should read:

“Scores range from 13 (normal) to 0 (total incapacitation) and define stages of the disease: HD1 (TFC 11–13), HD2 (TFC 7–10), HD3 (TFC 3–6), HD4 (1–2), and HD5 (0).”



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021